Generated by AI
Summary of Feb 27's posts. Generated by AI.
Summary of Nov 7's posts. Generated by AI.
Summary of Feb 27's posts. Generated by AI.
Investors talking about FLGT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.
Fulgent Genetics, Inc. is a healthcare diagnostics company that provides molecular testing, genetic testing, and anatomic pathology services to physicians, hospitals, and medical institutions. Its offerings cover a broad range of clinical areas, including hereditary cancer, reproductive health, oncology, gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology. The company also provides sequencing-based solutions and laboratory services designed to support clinically actionable medical decision-making. In addition to its diagnostic business, Fulgent Genetics, Inc. operates therapeutic development activities focused on cancer-related drug candidates. Headquartered in El Monte, California, the company serves customers in the United States and internationally and plays a role in combining laboratory testing, bioinformatics, and specialized pathology services within the broader precision medicine market.
Website4399 Santa Anita Avenue
El Monte, CA, 91731
United States
The latest articles about FLGT.
Fulgent Genetics Inc (FLGT) posted $90.4 million in Q3 2026 revenue, narrowed its non-GAAP loss guidance on disciplined spending, and advanced its AI pathology and therapeutic development initiatives.